586412-86-4Relevant articles and documents
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00359, (2020/09/27)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
-
Paragraph 0515; 0516, (2018/04/18)
Compounds of general formula (Ia), compounds of general formula (Ia′), compounds of general formula (Ib), compounds of general formula (Ib′), compounds of general formula (I), compounds of general formula (I′), and their pharmaceutically acceptable salts,
3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors
Lovell, Peter J.,Blaney, Frank E.,Goodacre, Caroline J.,Scott, Claire M.,Smith, Paul W.,Starr, Kathryn R.,Thewlis, Kevin M.,Vong, Antonio K.K.,Ward, Simon E.,Watson, Jeannette M.
, p. 1033 - 1036 (2007/10/03)
Investigation of halogen substitution in lead compound 1 has led to the identification of analogues which combine high affinity for 5-HT1A receptors and potent serotonin reuptake inhibitory activity. Several compounds show an improved selectivity over 5-HT1B and 5-HT1D receptors and a superior pharmacokinetic profile in the rat.
